Tauriga Sciences, Inc. Reports Continued Surge in its E-Commerce Business Segment

On Sunday March 29, 2020 - The Company Set New Daily Records for: Revenue Generated and Number of Individual Transactions

NEW YORK, NY, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today confirmed that its E-Commerce business segment is continuing to show strength and rapid growth.  On Sunday March 29, 2020, the Company set new daily records for both its E-Commerce revenue generated as well as number of individual transactions. For the first time, the Company generated in excess of $4,000 in daily E-Commerce revenue.  The E-Commerce business segment, is by far, the Company’s highest margin source of revenue.     

In other news, the Company has committed to donate 25 cents (“$0.25”) per Tauri-Gum™ Blister Pack sold (exclusively pertaining to its E-Commerce business), to the United Way COVID-19 Community Response and Recovery Fund.  This commitment will be valid for the following period: April 1, 2020 – December 31, 2020. An initial contribution from the Company has already been processed.   

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases.  This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™.  The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE.  During December of 2019, the Company announced that it completed the initial production run (thereby expanding its existing product lines) with the introduction of a 25mg Vegan CBD Isolate Infused vegan gummy (“gum drop”), branded under the name: Tauri-Gummies™.  Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model.  The Company has also announced the development of a Cannabigerol (“CBG”) Isolate infused version of Tauri-Gum™.  The flavor that has been selected is Peach-Lemon and each piece of gum contains 10mg of CBG Isolate / Each blister pack contains 80mg of CBG Isolate.  The Company announced, on March 24, 2020, that it completed payment for the entirety of its initial production run of its CBG version of Tauri-Gum™ (commercial launch – April 2020).  Please visit our corporate website at .

In addition - During March 2019, the Company announced the official launch of its E-Commerce site - as part of its Tauri-Gum™ commercialization strategy.  This site can be accessed by visiting the following URL address:  

On January 13, 2020, the Company formed a wholly owned subsidiary called: Tauriga Pharma Corp.  This subsidiary is focused on the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment(s)).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.

The Company has established corporate offices in both New York City (USA) and Barcelona (Spain) and operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. 

DISCLAIMER -- Forward-Looking Statements



This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

CONTACT INFORMATION



Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: 

cell # (917) 796 9926

Corp. Website:   

E-Commerce Website: